Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945590 | 1.00 | FFAR1 (0.39) | FFAR1MMECES2CES1CTSA | |
| SCHEMBL28891058 | 0.87 | MAPT (0.37) | MMECES2CES1APPAPLNR | |
| SCHEMBL30161268 | 0.87 | MAPT (0.37) | MMECES2CES1APPAPLNR | |
| SCHEMBL20967686 | 0.87 | MAPT (0.37) | MMECES2CES1APPAPLNR | |
| SCHEMBL22397218 | 0.85 | DRD2 (0.35) | FFAR1MMECES2CES1APP | |
| SCHEMBL30604027 | 0.83 | HDAC4 (0.32) | MMECES2CES1APPAPLNR | |
| SCHEMBL20945779 | 0.83 | HDAC4 (0.32) | MMECES2CES1APPAPLNR | |
| SCHEMBL20945777 | 0.83 | HDAC4 (0.32) | MMECES2CES1APPAPLNR | |
| SCHEMBL28608240 | 0.83 | FFAR1 (0.51) | FFAR1PPARG | |
| SCHEMBL18704145 | 0.82 | FFAR1 (0.47) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3704097-B1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3704097-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | FFAR1 4495/4885MME 3695/4885CES2 3471/4885 |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | FFAR1 4495/4885MME 3695/4885CES2 3471/4885 |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | FFAR1 4495/4885MME 3695/4885CES2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.